TERADYNE, INC.
TER · Healthcare · $54.6B mkt cap · FY2025 filings · Narrow moat ·
On the watchlist
The five investor questions
2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $3.7B to $3.2B, decreasing; diluted EPS 5.53 to 3.47, decreasing.
Median gross margin 58.2% over 10y, very stable.
Median ROIC 34.3%, above the 12% hurdle in 90% of years.
Net cash position — no leverage risk.
Owner earnings trend unclear.
Price vs. conservative owner-earnings floor
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- Owner earnings (normalized)
- $554M
- Owner-earnings floor / share
- $39.44
- Capped-growth comparison / share
- $39.44
- Recent price
- $349.92
- Price vs. owner-earnings floor
- 787% above owner-earnings floor
What today’s price assumes: owner earnings growing ~55%/yr over 5 years. The floor assumes owner earnings stay flat (0% growth).
How to read this
We solve for the constant annual change in owner earnings that would make the five-year floor equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.
This floor assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 239% above the floor across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or floor: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth floor 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
19 years of fundamentals
The business, in plain English
TERADYNE, INC. booked $3.2B of revenue in FY2025 in the Healthcare sector and kept 58.2% of it as gross profit — a high-margin business by that measure. After every other cost, 17.4% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $1.1B (FY2008) to $3.2B (FY2025) — about 6.4% a year compounded over 17 years.
It earned 21.1% on invested capital in the latest filed year, FY2025. Across the full 18-year measurable filed record, median ROIC was 21.8%. Over the v3 recent window (10 measurable filed years), median ROIC was 34.3%. The Returns on Capital filter above scores it 97/100.
The balance sheet carried $200M of total debt in FY2025 against $554M of owner earnings — roughly 0.4 years of owner earnings to retire it all. Balance-Sheet Safety scores it 100/100.
Put together: Balance-Sheet Safety is the strongest of the five filters (100/100) and Business Trend the weakest (23/100), which is how TER lands at 76/100 — a Narrow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in TER’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Track record
How TERADYNE, INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored TER on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the 4 years TER rated Wide-moat (2021, 2022, 2023 and 2024), the median forward total return that followed — measured only after each year’s filings were public — was:
- 1 year 22% vs the S&P 500’s 20% (price basis) · median over 4 years
- 3 years 61% vs the S&P 500’s 51% (price basis) · median over 2 years
- 5 years None of the 4 years it rated Wide has a fully elapsed 5-year window with a benchmark to compare against yet.
These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.
Healthcare context
#37 of 728 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #35UTMD UTAH MEDICAL PRODUCTS INC77.0 out of 100, Narrow moatNarrow moat
- #36LDDD LONGDUODUO COMPANY LIMITED76.4 out of 100, Narrow moatNarrow moat
- #38AME AMETEK, Inc.75.8 out of 100, Narrow moatNarrow moat
- #39EW EDWARDS LIFESCIENCES CORPORATION75.6 out of 100, Narrow moatNarrow moat
Compare TER with its nearest peers →All Healthcare companies on the Index →
Common questions about TER
- Does TERADYNE, INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores TERADYNE, INC. (TER) 76.1 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 23, pricing power 97, returns on capital 97, balance-sheet safety 100, capital discipline 64.
- Is TER trading below the conservative owner-earnings estimate?
- The conservative owner-earnings floor is $39.44 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $349.92, that is 787% above owner-earnings floor. The model also publishes a capped-growth comparison, but the floor is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
- How has TER's Moat Score changed over time?
- The record logs 16 readings since Jul 17, 2026; the latest reads 76.1 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.